abt-702 Search Results


abt 702 dihydrochloride  (MedChemExpress)
94
MedChemExpress abt 702 dihydrochloride
A MK2-deficient MEFs transduced with MK2 expression or control vector were treated with different doses of 5-ITu in the presence or absence of TNF (10 ng/ml) for 6 h. B Cells of the indicated genotype were treated with 10 µM 5-ITu for 6 and 24 h and cell viability was quantified. C MK2-deficient MEFs transduced with MK2 expression or control vector were treated with indicated small molecules (5 µM <t>ABT-702,</t> 100 nM gemcitabine, 5 µM etoposid, 5 µM doxorubicin and 5 µM staurosporine) in the presence or absence of TNF for 6 h and cell viability was assessed. D MK2-deficient MEFs transduced with MK2 expression or control vector were treated as indicated and viability was quantified after 6 h treatment. E , F RAW264.7 cells were treated as indicated to monitor the effect of 5-ITu in LPS-induced necroptosis ( E ) and SM-mediated autocrine TNF-dependent death ( F ). Average values of n = 3 independent wells are plotted ± SD (** p ≤ 0.001, *** p ≤ 0.0001, **** p ≤ 0.0001).
Abt 702 Dihydrochloride, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abt-702/ABT-702+dihydrochloride/pmc10372004-197-97-100
Average 94 stars, based on 1 article reviews
abt 702 dihydrochloride - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier
abt 702  (MuseChem Chemicals)
N/A
The first, non-nucleoside adenosine kinase (ADK) inhibitor (IC50 value 2 nM and 50 nM in cytosolic and intact cell assays, respectively). ABT702 is orally active to reduce pain and inflammation in animal models, yet found
   Buy from Supplier
abt 702 dihydrochloride  (Selleck Chemicals)
91
Selleck Chemicals abt 702 dihydrochloride
A MK2-deficient MEFs transduced with MK2 expression or control vector were treated with different doses of 5-ITu in the presence or absence of TNF (10 ng/ml) for 6 h. B Cells of the indicated genotype were treated with 10 µM 5-ITu for 6 and 24 h and cell viability was quantified. C MK2-deficient MEFs transduced with MK2 expression or control vector were treated with indicated small molecules (5 µM <t>ABT-702,</t> 100 nM gemcitabine, 5 µM etoposid, 5 µM doxorubicin and 5 µM staurosporine) in the presence or absence of TNF for 6 h and cell viability was assessed. D MK2-deficient MEFs transduced with MK2 expression or control vector were treated as indicated and viability was quantified after 6 h treatment. E , F RAW264.7 cells were treated as indicated to monitor the effect of 5-ITu in LPS-induced necroptosis ( E ) and SM-mediated autocrine TNF-dependent death ( F ). Average values of n = 3 independent wells are plotted ± SD (** p ≤ 0.001, *** p ≤ 0.0001, **** p ≤ 0.0001).
Abt 702 Dihydrochloride, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abt-702/ABT+702+dihydrochloride/pmc10372004-197-97-121
Average 91 stars, based on 1 article reviews
abt 702 dihydrochloride - by Bioz Stars, 2026-09
91/100 stars
  Buy from Supplier
abt 702  (Tocris)
93
Tocris abt 702
A MK2-deficient MEFs transduced with MK2 expression or control vector were treated with different doses of 5-ITu in the presence or absence of TNF (10 ng/ml) for 6 h. B Cells of the indicated genotype were treated with 10 µM 5-ITu for 6 and 24 h and cell viability was quantified. C MK2-deficient MEFs transduced with MK2 expression or control vector were treated with indicated small molecules (5 µM <t>ABT-702,</t> 100 nM gemcitabine, 5 µM etoposid, 5 µM doxorubicin and 5 µM staurosporine) in the presence or absence of TNF for 6 h and cell viability was assessed. D MK2-deficient MEFs transduced with MK2 expression or control vector were treated as indicated and viability was quantified after 6 h treatment. E , F RAW264.7 cells were treated as indicated to monitor the effect of 5-ITu in LPS-induced necroptosis ( E ) and SM-mediated autocrine TNF-dependent death ( F ). Average values of n = 3 independent wells are plotted ± SD (** p ≤ 0.001, *** p ≤ 0.0001, **** p ≤ 0.0001).
Abt 702, supplied by Tocris, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abt-702/ABT+702+hydrochloride/pmc07031697-29-0-2
Average 93 stars, based on 1 article reviews
abt 702 - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier
abt-702  (Merck KGaA)
90
Merck KGaA abt-702
A MK2-deficient MEFs transduced with MK2 expression or control vector were treated with different doses of 5-ITu in the presence or absence of TNF (10 ng/ml) for 6 h. B Cells of the indicated genotype were treated with 10 µM 5-ITu for 6 and 24 h and cell viability was quantified. C MK2-deficient MEFs transduced with MK2 expression or control vector were treated with indicated small molecules (5 µM <t>ABT-702,</t> 100 nM gemcitabine, 5 µM etoposid, 5 µM doxorubicin and 5 µM staurosporine) in the presence or absence of TNF for 6 h and cell viability was assessed. D MK2-deficient MEFs transduced with MK2 expression or control vector were treated as indicated and viability was quantified after 6 h treatment. E , F RAW264.7 cells were treated as indicated to monitor the effect of 5-ITu in LPS-induced necroptosis ( E ) and SM-mediated autocrine TNF-dependent death ( F ). Average values of n = 3 independent wells are plotted ± SD (** p ≤ 0.001, *** p ≤ 0.0001, **** p ≤ 0.0001).
Abt 702, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abt-702/abt702/pmc07957171-27-0-3
Average 90 stars, based on 1 article reviews
abt-702 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier
abt 702 hydrochloride  (Bio-Techne corporation)
89
Bio-Techne corporation abt 702 hydrochloride
A MK2-deficient MEFs transduced with MK2 expression or control vector were treated with different doses of 5-ITu in the presence or absence of TNF (10 ng/ml) for 6 h. B Cells of the indicated genotype were treated with 10 µM 5-ITu for 6 and 24 h and cell viability was quantified. C MK2-deficient MEFs transduced with MK2 expression or control vector were treated with indicated small molecules (5 µM <t>ABT-702,</t> 100 nM gemcitabine, 5 µM etoposid, 5 µM doxorubicin and 5 µM staurosporine) in the presence or absence of TNF for 6 h and cell viability was assessed. D MK2-deficient MEFs transduced with MK2 expression or control vector were treated as indicated and viability was quantified after 6 h treatment. E , F RAW264.7 cells were treated as indicated to monitor the effect of 5-ITu in LPS-induced necroptosis ( E ) and SM-mediated autocrine TNF-dependent death ( F ). Average values of n = 3 independent wells are plotted ± SD (** p ≤ 0.001, *** p ≤ 0.0001, **** p ≤ 0.0001).
Abt 702 Hydrochloride, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 89/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/abt-702/ABT+702+hydrochloride/custom%402372%4031767171
Average 89 stars, based on 1 article reviews
abt 702 hydrochloride - by Bioz Stars, 2026-09
89/100 stars
  Buy from Supplier
abt-702  (TargetMol)
N/A
   Buy from Supplier
abt-702 hydrochloride  (TargetMol)
N/A
   Buy from Supplier
abt 702 dihydrochloride  (BOC Sciences)
N/A
ABT 702 Dihydrochloride is a potent and selective non-nucleoside adenosine kinase inhibitor with IC50 value of 1.7 nM. ABT 702 displays oral activity in animal models of pain and inflammation. In Mar 2005, ABT 702
   Buy from Supplier
abt 702 dihydrochloride  (Aladdin Scientific Corporation)
N/A
InformationABT 702 dihydrochloride ABT-702 is a novel, potent non-nucleoside Adenosine kinase inhibitor with an IC50 of 1.7 nM. It has oral activity in animal models of pain and inflammation.Targetsadenosine kinase 1.7 nM
   Buy from Supplier
abt 702  (BOC Sciences)
N/A
ABT 702 is a non-nucleoside adenosine kinase (ADK) inhibitor (IC50 = 2 nM and 50 nM in cytosolic and intact cell assays, respectively). Study conformed that ABT702 could reduce pain and inflammation in animal models,
   Buy from Supplier
abt-702  (Aladdin Scientific Corporation)
N/A
   Buy from Supplier

Image Search Results


A MK2-deficient MEFs transduced with MK2 expression or control vector were treated with different doses of 5-ITu in the presence or absence of TNF (10 ng/ml) for 6 h. B Cells of the indicated genotype were treated with 10 µM 5-ITu for 6 and 24 h and cell viability was quantified. C MK2-deficient MEFs transduced with MK2 expression or control vector were treated with indicated small molecules (5 µM ABT-702, 100 nM gemcitabine, 5 µM etoposid, 5 µM doxorubicin and 5 µM staurosporine) in the presence or absence of TNF for 6 h and cell viability was assessed. D MK2-deficient MEFs transduced with MK2 expression or control vector were treated as indicated and viability was quantified after 6 h treatment. E , F RAW264.7 cells were treated as indicated to monitor the effect of 5-ITu in LPS-induced necroptosis ( E ) and SM-mediated autocrine TNF-dependent death ( F ). Average values of n = 3 independent wells are plotted ± SD (** p ≤ 0.001, *** p ≤ 0.0001, **** p ≤ 0.0001).

Journal: Cell Death Discovery

Article Title: 5-Iodotubercidin sensitizes cells to RIPK1-dependent necroptosis by interfering with NFκB signaling

doi: 10.1038/s41420-023-01576-x

Figure Lengend Snippet: A MK2-deficient MEFs transduced with MK2 expression or control vector were treated with different doses of 5-ITu in the presence or absence of TNF (10 ng/ml) for 6 h. B Cells of the indicated genotype were treated with 10 µM 5-ITu for 6 and 24 h and cell viability was quantified. C MK2-deficient MEFs transduced with MK2 expression or control vector were treated with indicated small molecules (5 µM ABT-702, 100 nM gemcitabine, 5 µM etoposid, 5 µM doxorubicin and 5 µM staurosporine) in the presence or absence of TNF for 6 h and cell viability was assessed. D MK2-deficient MEFs transduced with MK2 expression or control vector were treated as indicated and viability was quantified after 6 h treatment. E , F RAW264.7 cells were treated as indicated to monitor the effect of 5-ITu in LPS-induced necroptosis ( E ) and SM-mediated autocrine TNF-dependent death ( F ). Average values of n = 3 independent wells are plotted ± SD (** p ≤ 0.001, *** p ≤ 0.0001, **** p ≤ 0.0001).

Article Snippet: The following reagents were used for cell treatments at given concentrations: LPS ( Escherichia coli O55:B5, #L2880, Sigma-Aldrich, 100 ng ml −1 ), recombinant human TNFα (rHuTNF, #50435.50, Biomol, 10 ng/ml), Birinapant/SM (#HY-16591, MedChem Express, 1 μM), pan-caspase inhibitor zVAD-fmk (#4026865.0005, Bachem, 25 μM), MK2 inhibitor PF3644022 (#4279, Tocris, 5 μM), RIPK1 inhibitor Nec-1 (#BML-AP309-0020, Enzo Life Sciences, 50 μM), RIPK1 inhibitor Nec-1s (# 10-4544-5 mg, Tebu-Bio, 50 μM), RIPK3 inhibitor GSK872 (#HY-101872, MedChem Express, 5 μM), IKKβ inhibitor BMS345541 (#Axon 1731, Axon Medchem, 5 μM), TBK1/IKKε inhibitor BX795 (#T1830, Tebu-Bio), 5-Iodotubercidin (#HY-15424, MedChem Express, 2.5–10 μM), ABT-702 dihydrochloride (#HY-103161, MedChem Express, 5 μM), Staurosporine (#81590, Cayman, 5 μM), Etoposide (#E1383, Sigma, 5 μM), Doxorubicin (#15007, Cayman, 5 μM), Gemcitabine (#S1714, Selleckchem, 100 nM).

Techniques: Transduction, Expressing, Control, Plasmid Preparation

A MK2-deficient MEFs transduced with MK2 expression or control vector were treated with different doses of 5-ITu in the presence or absence of TNF (10 ng/ml) for 6 h. B Cells of the indicated genotype were treated with 10 µM 5-ITu for 6 and 24 h and cell viability was quantified. C MK2-deficient MEFs transduced with MK2 expression or control vector were treated with indicated small molecules (5 µM ABT-702, 100 nM gemcitabine, 5 µM etoposid, 5 µM doxorubicin and 5 µM staurosporine) in the presence or absence of TNF for 6 h and cell viability was assessed. D MK2-deficient MEFs transduced with MK2 expression or control vector were treated as indicated and viability was quantified after 6 h treatment. E , F RAW264.7 cells were treated as indicated to monitor the effect of 5-ITu in LPS-induced necroptosis ( E ) and SM-mediated autocrine TNF-dependent death ( F ). Average values of n = 3 independent wells are plotted ± SD (** p ≤ 0.001, *** p ≤ 0.0001, **** p ≤ 0.0001).

Journal: Cell Death Discovery

Article Title: 5-Iodotubercidin sensitizes cells to RIPK1-dependent necroptosis by interfering with NFκB signaling

doi: 10.1038/s41420-023-01576-x

Figure Lengend Snippet: A MK2-deficient MEFs transduced with MK2 expression or control vector were treated with different doses of 5-ITu in the presence or absence of TNF (10 ng/ml) for 6 h. B Cells of the indicated genotype were treated with 10 µM 5-ITu for 6 and 24 h and cell viability was quantified. C MK2-deficient MEFs transduced with MK2 expression or control vector were treated with indicated small molecules (5 µM ABT-702, 100 nM gemcitabine, 5 µM etoposid, 5 µM doxorubicin and 5 µM staurosporine) in the presence or absence of TNF for 6 h and cell viability was assessed. D MK2-deficient MEFs transduced with MK2 expression or control vector were treated as indicated and viability was quantified after 6 h treatment. E , F RAW264.7 cells were treated as indicated to monitor the effect of 5-ITu in LPS-induced necroptosis ( E ) and SM-mediated autocrine TNF-dependent death ( F ). Average values of n = 3 independent wells are plotted ± SD (** p ≤ 0.001, *** p ≤ 0.0001, **** p ≤ 0.0001).

Article Snippet: The following reagents were used for cell treatments at given concentrations: LPS ( Escherichia coli O55:B5, #L2880, Sigma-Aldrich, 100 ng ml −1 ), recombinant human TNFα (rHuTNF, #50435.50, Biomol, 10 ng/ml), Birinapant/SM (#HY-16591, MedChem Express, 1 μM), pan-caspase inhibitor zVAD-fmk (#4026865.0005, Bachem, 25 μM), MK2 inhibitor PF3644022 (#4279, Tocris, 5 μM), RIPK1 inhibitor Nec-1 (#BML-AP309-0020, Enzo Life Sciences, 50 μM), RIPK1 inhibitor Nec-1s (# 10-4544-5 mg, Tebu-Bio, 50 μM), RIPK3 inhibitor GSK872 (#HY-101872, MedChem Express, 5 μM), IKKβ inhibitor BMS345541 (#Axon 1731, Axon Medchem, 5 μM), TBK1/IKKε inhibitor BX795 (#T1830, Tebu-Bio), 5-Iodotubercidin (#HY-15424, MedChem Express, 2.5–10 μM), ABT-702 dihydrochloride (#HY-103161, MedChem Express, 5 μM), Staurosporine (#81590, Cayman, 5 μM), Etoposide (#E1383, Sigma, 5 μM), Doxorubicin (#15007, Cayman, 5 μM), Gemcitabine (#S1714, Selleckchem, 100 nM).

Techniques: Transduction, Expressing, Control, Plasmid Preparation